Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delayed Consent for Research During the Emergent Care of Febrile Young Infants: Feasible, Acceptable, Doable.

Pediatric emergency care·2026
Same author

Prevalence of Invasive Bacterial Infections Among Febrile Infants Aged 60 to 90 Days: A Systematic Review and Meta-Analysis.

JAMA pediatrics·2026
Same author

Bacteremia and Bacterial Meningitis Among Low-Risk Febrile Infants Aged 29 to 60 Days.

JAMA pediatrics·2026
Same author

Diagnostic Accuracy of Risk-Stratification Strategies for Premature Febrile Infants 8-60 Days Old.

Hospital pediatrics·2026
Same author

Eligibility for redirection from the pediatric emergency department: a qualitative study of professional and leader perspectives.

Pediatric research·2026
Same author

Frequency and Predictors of Persisting Symptoms 1 Year After Early Childhood Concussion.

Pediatrics·2026

Related Experiment Video

Updated: Jul 4, 2026

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

Atrial structural remodeling as an antiarrhythmic target.

Brett Burstein1, Stanley Nattel

  • 1Research Center and Department of Medicine, Montreal Heart Institute and Université de Montréal, Montréal, Canada.

Journal of Cardiovascular Pharmacology
|July 3, 2008
PubMed
Summary

Atrial fibrillation (AF) management is improving with upstream therapies targeting atrial fibrosis. These approaches address the underlying structural changes that promote AF, offering a promising alternative to conventional treatments.

Related Experiment Videos

Last Updated: Jul 4, 2026

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice
08:05

Optimization of Transesophageal Atrial Pacing to Assess Atrial Fibrillation Susceptibility in Mice

Published on: June 29, 2022

Area of Science:

  • Cardiology
  • Pharmacology
  • Biomedical Engineering

Background:

  • Atrial fibrillation (AF) is a common arrhythmia with limited treatment options.
  • Conventional antiarrhythmic drugs have poor efficacy and significant risks, including proarrhythmia.
  • Atrial fibrosis is a key factor in AF development and progression.

Purpose of the Study:

  • To review pharmacologic strategies targeting atrial fibrosis and structural remodeling in AF.
  • To explore the interplay of angiotensin II signaling, inflammation, and oxidative stress in AF pathogenesis.
  • To highlight novel therapeutic approaches for AF management.

Main Methods:

  • Review of experimental and clinical data on AF pathogenesis and treatment.
  • Analysis of pharmacologic interventions aimed at attenuating atrial fibrosis.
  • Focus on upstream therapies targeting the AF substrate.

Main Results:

  • Atrial fibrosis is a significant contributor to AF.
  • Angiotensin II signaling, inflammation, and oxidative stress are implicated in AF-related structural remodeling.
  • Pharmacologic strategies targeting these pathways show promise in preclinical and clinical studies.

Conclusions:

  • Targeting atrial fibrosis represents a promising "upstream" therapeutic strategy for AF.
  • Interventions modulating angiotensin II signaling, inflammation, and oxidative stress may reduce AF burden.
  • Further research into these pharmacologic approaches could lead to improved AF management.